STOCK TITAN

PTC Therapeutics: Mark Elliott Boulding sells 2,812 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) EVP and CLO Mark Elliott Boulding exercised options for 2,812 common shares at $25.69 per share on November 16, 2026, then sold 2,812 shares in three reported sale lots: 1,315 at a weighted average $61.39, 1,288 at $62.22, and 209 at $62.90 per share. The sale prices were weighted averages across multiple trades. The transactions were made under a written Rule 10b5-1 plan adopted September 10, 2025. After the exercise, the reported option position was 14,064 shares, with an expiration date of February 14, 2034.

Insider Boulding Mark Elliott
Role EXEC. VP AND CLO
Sold 2,812 shs ($174K)
Approx. gross sale proceeds $174K
Approx. exercise cost $72K
Approx. pre-tax spread $102K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F5 2,812 $0.00 $0.00
Exercise Common Stock F1 2,812 $25.69 $72K
Sale Common Stock F1, F2 1,315 $61.39 $81K
Sale Common Stock F1, F3 1,288 $62.22 $80K
Sale Common Stock F1, F4 209 $62.90 $13K
Holdings After Transaction: Stock Option (Right to Buy) — 14,064 options (Direct); Common Stock — 105,272 shares (Direct)
Footnotes (5)
  1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
  2. F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.87 to $61.76 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.89 to $62.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.90 to $63.00 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  5. F5. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Shares acquired through option exercise 2,812 shares November 16, 2026
Exercise price $25.69 per share Options exercised November 16, 2026
Sale transaction 1,315 shares at a weighted average $61.39 per share November 16, 2026; trades ranged from $60.87 to $61.76 per share
Sale transaction 1,288 shares at a weighted average $62.22 per share November 16, 2026; trades ranged from $61.89 to $62.62 per share
Sale transaction 209 shares at a weighted average $62.90 per share November 16, 2026; trades ranged from $62.90 to $63.00 per share
Reported option position after exercise 14,064 shares Options expire February 14, 2034
Rule 10b5-1 plan regulatory
"written Rule 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"weighted average price of sale transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
exercise price financial
"conversion_or_exercise_price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests over four years financial
"vests over four years"
A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PTCT shares did Mark Elliott Boulding sell, and at what prices?

Mark Elliott Boulding sold 2,812 shares on November 16, 2026, in three reported transactions: 1,315 at a weighted average $61.39 (trades from $60.87 to $61.76), 1,288 at $62.22 (from $61.89 to $62.62), and 209 at $62.90 (from $62.90 to $63.00) per share. The sales were made under a written Rule 10b5-1 plan adopted September 10, 2025.

How many shares did Mark Elliott Boulding acquire through the PTCT option exercise?

On November 16, 2026, Boulding exercised options to acquire 2,812 common shares at a $25.69 exercise price per share. The reported option position following the transaction was 14,064 shares, and the options expire February 14, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boulding Mark Elliott

(Last)(First)(Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EXEC. VP AND CLO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)2,812A$25.69108,084D
Common Stock11/16/2026S(1)1,315D$61.39(2)106,769D
Common Stock11/16/2026S(1)1,288D$62.22(3)105,481D
Common Stock11/16/2026S(1)209D$62.9(4)105,272D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$25.6911/16/2026M(1)2,812 (5)02/14/2034Common Stock2,812$014,064D
Explanation of Responses:
1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.87 to $61.76 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.89 to $62.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.90 to $63.00 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
5. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
/s/ Avraham S. Adler, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading